<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643186</url>
  </required_header>
  <id_info>
    <org_study_id>ASUMH</org_study_id>
    <nct_id>NCT02643186</nct_id>
  </id_info>
  <brief_title>Vaginal Misoprostol Versus Bilateral Uterine Artery Ligation in Decreasing Blood Loss in Trans-abdominal Myomectomy</brief_title>
  <official_title>Vaginal Misoprostol Versus Bilateral Uterine Artery Ligation in Decreasing Blood Loss in Trans-abdominal Myomectomy , a Randomized Control Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams Maternity Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams Maternity Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims at comparison between the effect of preoperative misoprostol and bilateral
      uterine artery ligation regarding their effect to decrease blood loss in transabdominal
      myomectomy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>estimated intraoperative blood loss measured in milliliters</measure>
    <time_frame>60 min</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the need of intra-operative blood transfusion</measure>
    <time_frame>60 min</time_frame>
    <description>Below a hemoglobin concentration of 7 g/dL requiring blood transfusion. It is indicated when intra-operative blood loss exceeds 15% of the patient's estimated blood volume, which is equal to the patient's weight in kilograms multiplied by 10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the need for conversion from myomectomy to hysterectomy</measure>
    <time_frame>60 min</time_frame>
    <description>It is indicated when there is uncontrolled intra-operative hemorrhage affecting the patient's vital signs and not responsive to conservative measures when it is impossible to reconstruct the uterus because of the many defects left by the removal of multiple fibroids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operative time in minutes</measure>
    <time_frame>60 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraoperative or postoperative complications</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>differance between pre and post operative hemoglobin and hematocrit levels</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of hospital stay in days</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Vaginal Misoprostol and Bilateral Uterine Artery Ligation in Decreasing Blood Loss in Trans-abdominal Myomectomy</condition>
  <arm_group>
    <arm_group_label>misoprostol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>preoperative vaginal misoprostol in decreasing blood loss in transabdominal myomectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>uterine artery ligation group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bilateral uterine artery ligation in decreasing blood loss in transabdominal myomectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>preoperative vaginal misoprostol</intervention_name>
    <description>preoperative vaginal misoprostol 400 micrograms 1 hour before surgery</description>
    <arm_group_label>misoprostol group</arm_group_label>
    <other_name>cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bilateral uterine artery ligation</intervention_name>
    <description>bilateral ascending uterine artery ligation at the level of uterine isthmus with 2/0 vicryl sutures</description>
    <arm_group_label>uterine artery ligation group</arm_group_label>
    <other_name>devascularization</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women in the reproductive age (20-40 years) diagnosed as having uterine fibroids who
             are consenting to have trans- abdominal myomectomy in the postmenstrual period
             diagnosed by: clinical symptoms and signs:

          -  abnormal uterine bleeding (menorrhagia or/and metrorrhagia)

          -  pain (dull aching lower abdominal pain or dysmenorrhea)

          -  pressure symptoms (dyspareunia, dysuria, dyschezia or /and backache)

          -  progressive abdominal enlargement (abdominal swelling) ultrasound (abdominal or
             transvaginal) to confirm the clinical diagnosis:

          -  maximum diameter of the largest fibroid is greater than 4 cm

          -  maximum number of uterine myomas is not to be more than 5 myomas

          -  uterine fibroid may be subserous or intramural

        Exclusion Criteria:

          -  obesity (BMI &gt;30 kg/m2)

          -  cardiac, endocrine, pulmonary or hematological disease (including anemia; hemoglobin
             level below 10 gm/dl)

          -  patients known to be allergic to prostaglandin preparations

          -  patients who received preoperative hormonal therapy (GnRH analogue)

          -  patients presented by or with suspected malignant gynecological disease patients
             diagnosed as having submucous uterine fibroids, cervical or supracervical fibroids,
             broad ligamentary fibroids and pedunculated fibroids patients with contraindication to
             general anaesthesia

          -  patients with positive pregnancy test

          -  virgin patients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>walid basuony basuony, lecturer</last_name>
    <phone>01001763042</phone>
    <email>walidbasuony@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>walid basuony, lecturer</last_name>
      <phone>0100763042</phone>
      <email>walidbasuony@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>December 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>December 29, 2015</last_update_submitted>
  <last_update_submitted_qc>December 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams Maternity Hospital</investigator_affiliation>
    <investigator_full_name>aliaa mohamed ali</investigator_full_name>
    <investigator_title>university</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

